Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.
about
7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeysRolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memoryPharmacologic management of Alzheimer disease, Part I: Hormonal and emerging investigational drug therapies.Effect of vinpocetine (cognitol™) on cognitive performances of a nigerian population.Potential strategies against age-related brain deterioration. Dietary and pharmacological approaches.The effect of isoenzyme-selective PDE inhibitors on methacholine-induced contraction of guinea-pig and rat ileum.Fetal alcohol spectrum disorders and abnormal neuronal plasticity.Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.Clinical and molecular genetics of the phosphodiesterases (PDEs).The role of phytochemicals in the treatment and prevention of dementia.Quantitative Determination of Vinpocetine in Dietary Supplements.Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions.Oxiracetam or fastigial nucleus stimulation reduces cognitive injury at high altitude.Investigation of neuropsychopharmacological effects of a polyherbal formulation on the learning and memory process in rats.Horizontal component of electro-oculogram as a parameter of arousal in dementia: relationship between intellectual improvement and increasing arousal under pharmacotherapy."Brain-Specific" Nutrients: A Memory Cure?The novel nootropic compound DM232 (UNIFIRAM) ameliorates memory impairment in mice and rats
P2860
Q24561600-B539D20E-0097-491A-B7DE-C96FD60ECA83Q24644260-74AFD040-7E01-40C1-BA7D-F146FCFACCABQ33543110-DEA394AD-A350-4DD9-A4FD-EC7D1969F8C0Q34162473-3F9C7855-1E26-4651-8648-09CEF7FE452EQ35656634-6F41DE8B-47E9-4E2C-BAB6-D1A393DD42F5Q35874169-B930D819-BF38-48FA-80E5-A27E48102FB8Q35915502-B8EB15E8-F46C-409E-929C-3A92678E1257Q37625928-5CF268C9-E166-4908-B4D8-89C8AC50B9C4Q37657841-54F14AA2-C197-401B-B135-EEFAEC148B91Q37884566-76E2B658-D7A8-41DB-A0CE-5BF5C6BFDE85Q41888375-341CD02D-340C-41B4-8E04-4FE6BB708D27Q41903612-AE97FC75-53CA-4059-B7E6-2BB073B9C900Q42656037-810BEC01-FC72-4456-A37E-D2DF883C55B1Q42771684-F9B6FA42-0DDE-4A68-9ADC-176FA2AE7050Q52034204-87E03189-3DA0-44E5-B9CB-233CAF3FDEACQ53874687-452BCC68-8415-4558-AAC9-A49B8DC81751Q56514116-14697332-DC7F-4918-80C6-212178ED779C
P2860
Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacology of nootropics and ...... tion to their use in dementia.
@en
Pharmacology of nootropics and ...... tion to their use in dementia.
@nl
type
label
Pharmacology of nootropics and ...... tion to their use in dementia.
@en
Pharmacology of nootropics and ...... tion to their use in dementia.
@nl
prefLabel
Pharmacology of nootropics and ...... tion to their use in dementia.
@en
Pharmacology of nootropics and ...... tion to their use in dementia.
@nl
P2860
P356
P1433
P1476
Pharmacology of nootropics and ...... tion to their use in dementia.
@en
P2093
C D Nicholson
P2860
P2888
P304
P356
10.1007/BF02244119
P577
1990-01-01T00:00:00Z